Literature DB >> 10826837

Comparison of a clinic-based ELISA test kit with the immunofluorescence test for the assay of Ehrlichia canis antibodies in dogs.

T Waner1, C Strenger, A Keysary.   

Abstract

The "gold standard" for the detection of antibodies to Ehrlichia canis, the cause of canine monocytic ehrlichiosis (CME), is the indirect immunofluorescence antibody (IFA) test. The IFA test however is generally available only in selected laboratories and requires extensive equipment and trained personnel. A double-blind study was conducted to compare the ability of an in-clinic standardized enzyme-linked immunosorbent assay (ELISA) test kit to measure E. canis IgG antibodies in dogs compared with the standard IFA technique. A good correlation was found between the 2 techniques (r2 = 0.8793; P < 0.0001). Evidence for the sensitivity of the ELISA technique for the early detection of E. canis IgG antibodies was demonstrated by comparing the appearance of E. canis antibody titers by the IFA and ELISA techniques after artificial infection of 2 sets of dogs. In both experimental infections, both tests were equally sensitive for the early detection of IgG antibodies against E. canis, and the results correlated well with the appearance of fever and clinical signs. Proposed application of the in-clinic ELISA test is to aid in the diagnosis of CME.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10826837     DOI: 10.1177/104063870001200307

Source DB:  PubMed          Journal:  J Vet Diagn Invest        ISSN: 1040-6387            Impact factor:   1.279


  8 in total

1.  Serodetection of Ehrlichia canis infection in dogs from Ludhiana district of Punjab, India.

Authors:  L D Singla; Harkirat Singh; P Kaur; N D Singh; N K Singh; P D Juyal
Journal:  J Parasit Dis       Date:  2011-08-02

2.  Comparison of serological detection methods for diagnosis of Ehrlichia canis infections in dogs.

Authors:  Myriam Bélanger; Heather L Sorenson; Michelle K France; Michael V Bowie; Anthony F Barbet; Edward B Breitschwerdt; A Rick Alleman
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

3.  Characterization of the major antigenic protein 2 of Ehrlichia canis and Ehrlichia chaffeensis and its application for serodiagnosis of ehrlichiosis.

Authors:  Tamece T Knowles; A Rick Alleman; Heather L Sorenson; David C Marciano; Edward B Breitschwerdt; Shimon Harrus; Anthony F Barbet; Myriam Bélanger
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

4.  Seroprevalence and Risk Factors of Ehrlichia canis Infection among Companion Dogs of Mashhad, North East of Iran, 2009-2010.

Authors:  Maneli Ansari-Mood; Javad Khoshnegah; Mehrdad Mohri; Seyed Mehdi Rajaei
Journal:  J Arthropod Borne Dis       Date:  2015-03-11       Impact factor: 1.198

5.  Clinical and hematobiochemical response in canine monocytic ehrlichiosis seropositive dogs of Punjab.

Authors:  Manasa R Kottadamane; Pritpal Singh Dhaliwal; Lachhman Das Singla; Baljinder Kumar Bansal; Sanjeev Kumar Uppal
Journal:  Vet World       Date:  2017-02-27

6.  Canine Monocytic Ehrlichiosis among working dogs of organised kennels in India: A comprehensive analyses of clinico-pathology, serological and molecular epidemiological approach.

Authors:  Mitesh Mittal; Krishnendu Kundu; Soumendu Chakravarti; Jajati K Mohapatra; Kapil Nehra; V K Sinha; B S Sanjeeth; C P Churamani; Anil Kumar
Journal:  Prev Vet Med       Date:  2017-08-25       Impact factor: 2.670

7.  Seroprevalence of Canine Ehrlichiosis and Microscopic Screening for Canine Babesiosis in Dogs in Harare, Zimbabwe, 2016-2017.

Authors:  Solomon Dhliwayo; Brighton Chihambakwe; Knowledge Taonezvi; Silvester M Chikerema; Musavengana T Tivapasi; Davies M Pfukenyi
Journal:  Vet Med Int       Date:  2019-12-01

8.  Glomerulotubular pathology in dogs with subclinical ehrlichiosis.

Authors:  Leandro Zuccolotto Crivellenti; Cristiane Alves Cintra; Suellen Rodrigues Maia; Gyl Eanes Barros Silva; Sofia Borin-Crivellenti; Rachel Cianciolo; Christopher A Adin; Mirela Tinucci-Costa; Caio Santos Pennacchi; Aureo Evangelista Santana
Journal:  PLoS One       Date:  2021-12-08       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.